Why Verve Therapeutics Is Skyrocketing Today

The Motley Fool·04/15/2025 16:43:00

Listen to the news

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.

Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Several analysts have now raised their price targets on the stock, and investors are buying up shares in response.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Verve Therapeutics stock sees a swell of bullish coverage

In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's analysts said that results for VERVE-102 had come in better than expected in terms of both safety and efficacy.

Guggenheim also published new coverage on Verve this morning -- maintaining a buy rating on the stock and raising its one-year price target from $18 per share to $24 per share. The firm's analysts cheered on the results for the Heart-2 Phase 1b trial and now sees a 75% chance that the treatment will be successfully marketed -- up from its previous estimate of 60%.

Canaccord was even more bullish. The firm reiterated a buy rating on the stock and increased its one-year price target from $32 per share to $39 per share, saying that safety and efficacy results for the treatment in the trial had knocked it out of the park.

What's next for Verve Therapeutics?

Verve is scheduled to share more information about VERVE-102 at a medical conference this quarter, including trial data from the treatment at a higher dosage level. With the treatment potentially delivering best-in-class results, Verve stock could have room to run above current levels.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English